Literature DB >> 1593678

Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: prospective study.

E Solsona1, I Iborra, J V Ricós, J L Monrós, R Dumont.   

Abstract

A prospective study was done to evaluate treatment of patients with muscle-infiltrating bladder cancer by transurethral resection exclusively. Inclusion criteria for this study were histological confirmation of muscular bladder infiltration, endoscopic radical transurethral resection, disappearance of hardened areas after transurethral resection, and negative biopsies of the depth and periphery of the tumor bed. The study began in April 1981. The average followup in series 1 (April 1981 to December 1986, 59 patients) was 55.4 months. Actually, of the patients 31 (52.5%) are without evidence of recurrence and 28 (47.5%) have recurrent disease. Of the latter patients 11 (18.6%) had invasive bladder recurrence, including 7 (11.9%) who had recurrence at 3 months, which indicated clinical understaging. Three patients (5%) had metastases without bladder tumor. The remaining 14 patients (23.7%) had superficial bladder recurrence. The overall survival rate was 83% (49 of 59 patients) and 43 patients (72.8%) still retain the bladder. The present data are confirmed by the results of series 2 (December 1986 to August 1989). Therefore, the data would justify conservative management in a selected group of patients with muscle-infiltrating bladder cancer.

Entities:  

Mesh:

Year:  1992        PMID: 1593678     DOI: 10.1016/s0022-5347(17)37612-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Current management of muscle-invasive bladder cancer.

Authors:  G Sancho; P Maroto; J Palou
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

2.  Intravenously administered vitamin C as cancer therapy: three cases.

Authors:  Sebastian J Padayatty; Hugh D Riordan; Stephen M Hewitt; Arie Katz; L John Hoffer; Mark Levine
Journal:  CMAJ       Date:  2006-03-28       Impact factor: 8.262

3.  SEOM clinical guidelines for the treatment of invasive bladder cancer.

Authors:  Rafael Morales; Albert Font; Joan Carles; Dolores Isla
Journal:  Clin Transl Oncol       Date:  2011-08       Impact factor: 3.405

4.  Transurethral resection and intra-arterial chemotherapy for muscle-invasive bladder cancer.

Authors:  J Kondás; L Engloner; L Váczi; G Kondér
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

5.  Radical cystectomy versus alternative treatments for muscle-confined bladder cancer.

Authors:  A Tekin; F T Aki; H Ozen
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 6.  The role of a second transurethral resection for high-grade bladder cancer.

Authors:  P Langenstroer; W See
Journal:  Curr Urol Rep       Date:  2000-10       Impact factor: 2.862

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.